The goal of this program is to improve the use of ovarian function sup pression (OFS) in patients with breast cancer, strategies to preserve fertility in patients receiving treatment for oncologic diseases, and management of breast cancer using antibody drug conjugates. After hearing and assimilating this program, the clinician will be better able to: 1. Outline the evidence from the Suppression of Ovarian Function Trial and TEXT trial comparing use of OFS and tamoxifen in breast cancer. 2. Interpret the clinical significance of different recurrence score ranges in patients with breast cancer to guide treatment decisions. 3. Compare risk for premature ovarian insufficiency with use of cyclophosphamide vs methotrexate. 4. Assess use of trastuzumab emtansine compared with trastuzumab in high-risk breast cancer patients as observed in the KATHERINE trial. 5. Explain the results using trastuzumab deruxtecan in patients with human epidermal growth factor receptor-low breast cancer, per the DESTINY-Breast04 trial.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-08-29 05:00:00
- End Date: 2024-08-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Medical Oncology